Divergence of the Response Induced by Xenogenic Immunization in the Sepsis Survival of Rats

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2015 May 19

PMID 25984763

Authors

Magdiel Perez-Cruz

Cristina Costa

Rafael Manez

Affiliations

Soon will be listed here.

Abstract

We have previously described that boosted natural xenoantibodies in rats cross-react to bacteria by targeting carbohydrate antigens. This type of immunization is associated with reduced survival after cecal ligation and puncture (CLP). In the present study, we investigated further this phenomenon by immunizing Lewis rats with three intraperitoneal injections, every other day, of hamster blood compared to saline-injected control animals. One day after the last injection, CLP was performed to produce a low-grade sepsis. Induction of xenoantibodies was associated with a reduction in animal survival after CLP relative to controls (45% vs. 90%, p<0.01). No bacterial blood load was observed after CLP in this model either with or without xenoantibody enhancement, indicating that the augmented mortality was not mediated by a direct effect of boosted xenoantibodies over blood bacteria. Nevertheless, the xenoimmunization produced a systemic inflammatory response in all rats. Additionally, a lack of weight gain at the time of CLP was present in animals that died after the procedure, which was not observed in surviving rats and controls. The cytokine profile at the time of CLP in animals that died after the procedure was characterized by an increase in the serum level of several cytokines, particularly adipokines. In contrast, the cytokine profile at CLP of xenoimmunized rats that survived the procedure was characterized by a reduction in the level of cytokines. In conclusion, this study failed to show a direct effect of boosted xenoantibodies over blood bacterial isolates as cause for the decreased survival after CLP. However, it evidenced that non-infectious systemic inflammation may lead to a pattern of augmented cytokines, particularly adipokines, which impairs survival after subsequent CLP. Therefore, the profile of cytokines existing before the infectious insult appears more crucial than that resulting from the condition for the outcome of sepsis.

References

Osuchowski M, Connett J, Welch K, Granger J, Remick D . Stratification is the key: inflammatory biomarkers accurately direct immunomodulatory therapy in experimental sepsis. Crit Care Med. 2009; 37(5):1567-73. PMC: 3670962. DOI: 10.1097/CCM.0b013e31819df06b. View

Draisma A, Pickkers P, Bouw M, van der Hoeven J . Development of endotoxin tolerance in humans in vivo. Crit Care Med. 2009; 37(4):1261-7. DOI: 10.1097/CCM.0b013e31819c3c67. View

Rittirsch D, Huber-Lang M, Flierl M, Ward P . Immunodesign of experimental sepsis by cecal ligation and puncture. Nat Protoc. 2009; 4(1):31-6. PMC: 2754226. DOI: 10.1038/nprot.2008.214. View

Skurnik D, Kropec A, Roux D, Theilacker C, Huebner J, Pier G . Natural antibodies in normal human serum inhibit Staphylococcus aureus capsular polysaccharide vaccine efficacy. Clin Infect Dis. 2012; 55(9):1188-97. PMC: 3529611. DOI: 10.1093/cid/cis624. View

Yamanaka Y, Gierahn T, Love J . The dynamic lives of T cells: new approaches and themes. Trends Immunol. 2012; 34(2):59-66. PMC: 3565007. DOI: 10.1016/j.it.2012.10.006. View

Deng M, Scott M, Loughran P, Gibson G, Sodhi C, Watkins S . Lipopolysaccharide clearance, bacterial clearance, and systemic inflammatory responses are regulated by cell type-specific functions of TLR4 during sepsis. J Immunol. 2013; 190(10):5152-60. PMC: 3644895. DOI: 10.4049/jimmunol.1300496. View

Fjell C, Thair S, Hsu J, Walley K, Russell J, Boyd J . Cytokines and signaling molecules predict clinical outcomes in sepsis. PLoS One. 2013; 8(11):e79207. PMC: 3828333. DOI: 10.1371/journal.pone.0079207. View

Perez-Cruz M, Costa C, Manez R . Boosted rat natural xenoantibodies cross-react with Enterococcus faecalis by targeting melibiose and L-rhamnose. J Innate Immun. 2013; 6(2):140-51. PMC: 6741499. DOI: 10.1159/000355305. View

Ebong S, Call D, Nemzek J, Bolgos G, NEWCOMB D, Remick D . Immunopathologic alterations in murine models of sepsis of increasing severity. Infect Immun. 1999; 67(12):6603-10. PMC: 97073. DOI: 10.1128/IAI.67.12.6603-6610.1999. View

10.

Ochsenbein A, Fehr T, Lutz C, Suter M, Brombacher F, Hengartner H . Control of early viral and bacterial distribution and disease by natural antibodies. Science. 1999; 286(5447):2156-9. DOI: 10.1126/science.286.5447.2156. View

11.

Krempler F, Breban D, Oberkofler H, Esterbauer H, Hell E, Paulweber B . Leptin, peroxisome proliferator-activated receptor-gamma, and CCAAT/enhancer binding protein-alpha mRNA expression in adipose tissue of humans and their relation to cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2000; 20(2):443-9. DOI: 10.1161/01.atv.20.2.443. View

12.

Cramer D . Natural antibodies and the host immune responses to xenografts. Xenotransplantation. 2000; 7(2):83-92. DOI: 10.1034/j.1399-3089.2000.00061.x. View

13.

Manez R, Blanco F, Diaz I, Centeno A, Lopez-Pelaez E, Hermida M . Removal of bowel aerobic gram-negative bacteria is more effective than immunosuppression with cyclophosphamide and steroids to decrease natural alpha-galactosyl IgG antibodies. Xenotransplantation. 2001; 8(1):15-23. DOI: 10.1034/j.1399-3089.2001.00082.x. View

14.

Takeda K, Kaisho T, Akira S . Toll-like receptors. Annu Rev Immunol. 2003; 21:335-76. DOI: 10.1146/annurev.immunol.21.120601.141126. View

15.

Galili U, Mandrell R, Hamadeh R, SHOHET S, Griffiss J . Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora. Infect Immun. 1988; 56(7):1730-7. PMC: 259469. DOI: 10.1128/iai.56.7.1730-1737.1988. View

16.

Hamadeh R, Jarvis G, Galili U, Mandrell R, Zhou P, Griffiss J . Human natural anti-Gal IgG regulates alternative complement pathway activation on bacterial surfaces. J Clin Invest. 1992; 89(4):1223-35. PMC: 442982. DOI: 10.1172/JCI115706. View

17.

Galili U, Anaraki F, Thall A, Radic M . One percent of human circulating B lymphocytes are capable of producing the natural anti-Gal antibody. Blood. 1993; 82(8):2485-93. View

18.

Mond J, Lees A, Snapper C . T cell-independent antigens type 2. Annu Rev Immunol. 1995; 13:655-92. DOI: 10.1146/annurev.iy.13.040195.003255. View

19.

Friedman J, Halaas J . Leptin and the regulation of body weight in mammals. Nature. 1998; 395(6704):763-70. DOI: 10.1038/27376. View

20.

Barbier M, Cherbut C, Aube A, Blottiere H, Galmiche J . Elevated plasma leptin concentrations in early stages of experimental intestinal inflammation in rats. Gut. 1998; 43(6):783-90. PMC: 1727345. DOI: 10.1136/gut.43.6.783. View